FHD-286   Click here for help

GtoPdb Ligand ID: 11967

Synonyms: FHD286
Compound class: Synthetic organic
Comment: FHD-286 is a first-in-class oral allosteric BAF complex inhibitor. It targets the SMARCA4 (BRG1) subunit of the complex. FHD-286 was developed by Foghorn Therapeutics, and its chemical structure was disclosed at the AACR spring meeting in 2022.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 11
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 181.37
Molecular weight 562.17
XLogP 1.94
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COC[C@@H](C(=O)Nc1scc(n1)c1cccc(n1)N1C[C@H](C)O[C@@H](C1)C)NC(=O)c1ccn(c1)S(=O)(=O)C
Isomeric SMILES COC[C@H](NC(=O)c1cn(cc1)S(=O)(=O)C)C(=O)Nc1nc(cs1)c1cccc(n1)N1C[C@H](C)O[C@H](C)C1
InChI InChI=1S/C24H30N6O6S2/c1-15-10-29(11-16(2)36-15)21-7-5-6-18(25-21)20-14-37-24(27-20)28-23(32)19(13-35-3)26-22(31)17-8-9-30(12-17)38(4,33)34/h5-9,12,14-16,19H,10-11,13H2,1-4H3,(H,26,31)(H,27,28,32)/t15-,16+,19-/m0/s1
InChI Key JBLQNFBXKOAIHG-FCEWJHQRSA-N
No information available.
Summary of Clinical Use Click here for help
FHD-286 will be evaluated for anti-cancer potential.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04891757 FHD-286 in Subjects With Advanced Hematologic Malignancies Phase 1 Interventional Foghorn Therapeutics Inc.
NCT04879017 FHD-286 in Subjects With Metastatic Uveal Melanoma Phase 1 Interventional Foghorn Therapeutics Inc.